Rna Targeting Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RNA targeting therapy encompasses a range of approaches to modulate gene expression at the RNA level, including antisense oligonucleotides (ASOs), RNA interference (RNAi), and small molecule RNA modulators. These therapies can reduce toxic protein expression, correct splicing defects, and restore normal gene function in neurodegenerative diseases.
'''RNA Targeting Therapy for Neurodegenerative Diseases''' leverages advances in RNA biology to modulate gene expression, reduce toxic protein levels, and correct disease-causing mutations. This page covers antisense oligonucleotides, RNA interference, small molecule modulators, and their applications in neurodegenerative disease treatment.
{| class="infobox"
|-
! colspan="2" style="background:#e8f4ea;font-size:120%;" | RNA Targeting Therapy
|-
| '''Category''' || Therapeutic Intervention
|-
| '''Target Conditions''' || ALS, HD, AD, PD, SMA, Ataxias
|-
| '''Mechanism''' || ASO, siRNA, miRNA, small molecules
|-
| '''Delivery Routes''' || Intrathecal, IV, Intranasal
|-
| '''Clinical Stage''' || Approved (SMA), Phase I-III
|-
| '''Key Successes''' || Spinraza, Teclesendan, Inotersen
|}
== Overview ==
RNA targeting therapies offer several advantages over traditional small molecule drugs:
- Can target "undruggable" proteins
- High specificity for target sequences
- Can modulate splice patterns
- Gene expression can be temporarily modulated
== Therapeutic Modalities ==
=== Antisense Oligonucleotides (ASOs) ===
Single-stranded DNA analogs that bind complementary RNA to:
- Promote RNA degradation
- Modulate splicing
- Block translation
- Alter miRNA function
Key Features:
- Chemical modifications (2'-O-methyl, phosphorodiamidate morpholino oligomers - PMOs, locked nucleic acids - LNAs)
- Gapmer design for RNase H recruitment
- Splicing-modulating ASOs
=== RNA Interference (RNAi) ===
Double-stranded RNA triggers sequence-specific mRNA cleavage:
- siRNA: Exogenously delivered 21-23 bp duplexes
- shRNA: Viral vector-expressed hairpin precursors
- miRNA mimics: Overexpress natural regulators
=== Small Molecule RNA Modulators ===
- RNA splice modulators (e.g., risdiplam for SMA)
- mRNA stabilizers/destabilizers
- Ribosome modulators
=== CRISPR RNA Editing ===
- Cas13 systems for RNA targeting
- Guide RNA delivery challenges
== Disease-Specific Applications ==
=== Amyotrophic Lateral Sclerosis (ALS) ===
SOD1 ASOs (BIIB067/tofersen)
- Targets SOD1 mutations (~20% of familial ALS)
- Reduces SOD1 protein in CSF
- Phase III completed, showed benefit in patients with faster progression
C9orf72 ASOs
- Targets hexanucleotide repeat expansions
- Reduces toxic RNA foci and dipeptide repeats
- Phase I/II ongoing
ATXN2 ASOs
- Targets intermediate polyQ expansions
- Modulates ALS risk
=== Spinal Muscular Atrophy (SMA) ===
Spinraza (nusinersen)
- Approved ASO modifying SMN2 splicing
- Increases functional SMN protein production
- Landmark success in CNS disease
Onasemnogene abeparvovec (Zolgensma)
- Gene therapy delivering SMN1
- Single-dose IV delivery
Risdiplam
- Small molecule splicing modifier
- Oral delivery
=== Huntington's Disease ===
ASOs targeting HTT
- Multiple programs in development
- Reduce mutant huntingtin protein
- Trials showed safety, efficacy signals
Allele-selective approaches
- Target mutant allele with SNP phasing
- Preserve wild-type function
=== Alzheimer's Disease ===
BACE1 ASOs
- Reduce BACE1 enzyme production
- Trials halted due to safety (cognitive worsening)
APOE ASOs
- Target APOE4 risk allele
- Reduce amyloid pathology
Tau ASOs
- Reduce tau protein expression
- Clinical trials ongoing
=== Parkinson's Disease ===
LRRK2 ASOs
- Target G2019S mutation
- Reduce LRRK2 kinase activity
Alpha-synuclein ASOs
- Reduce SNCA expression
- Prevent Lewy body formation
=== Ataxias ===
Ataxin-1 ASOs (SCN1A)
Ataxin-3 ASOs
- SCA3/MJD trials in preparation
Frataxin ASOs
- Friedreich's ataxia trials
== Clinical Trial Overview ==
{| class="wikitable"
|-
! Drug/Program
! Target
! Condition
! Stage
! Status
! PMID
|-
| Tofersen (BIIB067)
| SOD1
| ALS
| Phase III
| Approved
| 33218568 |
| Nusinersen |
| SMN2 |
| SMA |
| Approved |
| 27571880 |
| - |
| IONIS-HTTRx |
| HTT |
| HD |
| Phase I/II |
| Completed |
| 31785248 |
| - |
| BIIB080 |
| MAPT |
| AD |
| Phase I |
| Recruiting |
| — |
| - |
| WVE-004 |
| C9orf72 |
| ALS/FTD |
| Phase I/II |
| Recruiting |
| — |
| } |
== Delivery Challenges ==
- Blood-brain barrier: Most require intrathecal delivery
- Neuronal uptake: Limited by endosomal trapping
- Distribution: Ensuring widespread CNS coverage
- Repeat dosing: Long-term safety considerations
== Future Directions ==
- Conjugate therapies: GalNAc, peptide conjugates for CNS delivery
- Allele-selective: Target mutant allele specifically
- Combination approaches: ASO + small molecule
- Gene editing: CRISPR for permanent correction
== See Also ==
== References ==
- Bennett CF, et al. (2019). "Therapeutic antisense oligonucleotides for neurological disease." ''Neurobiology of Disease''. PMID:31228661
- Corey DR. (2017). "RNA therapeutics: Successes and challenges." ''ACS Chemical Biology''. PMID:29072563
- Miller T, et al. (2020). "Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS." ''New England Journal of Medicine''. PMID:33218568
- Finkel RS, et al. (2016). "Nusinersen treatment in infantile-onset SMA." ''Lancet''. PMID:27571880
- Tabrizi SJ, et al. (2019). "Targeting huntingtin protein in Huntington's disease." ''Neuron''. PMID:31785248
The study of Rna Targeting Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Lieberman AP, et al. RNA targeting and therapeutics for neurodegenerative disease. Nat Rev Neurol. 2019;15(11):647-661. PMID:31611656
- Sibley CR, Wood MJ. RNA targeting for neurodegenerative disorders. Gene Ther. 2012;19(4):295-306. PMID:22170341
- Xia X, et al. RNA-based therapeutics for neurodegenerative diseases. Adv Drug Deliv Rev. 2015;87:74-85. PMID:25888631
- Schoch KM, Miller TM. Antisense oligonucleotides for treatment of neurodegenerative disease. Ann Neurol. 2017;81(2):162-168. PMID:28029247
- Aartsma-Rus A, van Putten M. Antisense-mediated exon skipping for Duchenne muscular dystrophy. Prog Mol Biol Transl Sci. 2012;107:207-232. PMID:22482451